

# Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

## Calu-1

RRID:CVCL\_0608

Type: Cell Line

### Proper Citation

RRID:CVCL\_0608

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0608](https://web.expasy.org/cellosaurus/CVCL_0608)

**Proper Citation:** RRID:CVCL\_0608

**Description:** Cell line Calu-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Lung squamous cell carcinoma

**Defining Citation:** [PMID:327080](#), [PMID:833871](#), [PMID:3518877](#), [PMID:6582512](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:7459858](#), [PMID:7736387](#), [PMID:7972006](#), [PMID:8385084](#), [PMID:11583962](#), [PMID:12068308](#), [PMID:12794755](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:24002593](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26361996](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

**Comments:** Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** Calu-1

**Synonyms:** CaLu-1, CALU-1, Calu.1, CALU 1, Calu 1, CALU1, Calu1

**Cross References:** BTO:BTO\_0002940, CLO:CLO\_0002191, EFO:EFO\_0002151, CLDB:cl631, CLDB:cl632, CLDB:cl633, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-

MTAB-3610, ATCC:HTB-54, BioGRID\_ORCS\_Cell\_line:233, BioSample:SAMN03471732, BioSample:SAMN10988371, cancercellines:CVCL\_0608, CancerTools:161905, CCRID:3101HUMTCHu192, Cell\_Model\_Passport:SIDM01545, ChEMBL-Cells:ChEMBL3308031, ChEMBL-Targets:ChEMBL613505, CLS:300141, Cosmic:724858, Cosmic:755615, Cosmic:929968, Cosmic:933574, Cosmic:934465, Cosmic:934541, Cosmic:1089224, Cosmic:1146872, Cosmic:1188586, Cosmic:1434968, Cosmic:2060525, Cosmic:2125218, Cosmic:2645023, Cosmic:2646653, Cosmic:2668264, Cosmic:2772160, DepMap:ACH-000511, ECACC:93120818, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:724858, GEO:GSM108801, GEO:GSM108802, GEO:GSM206451, GEO:GSM253387, GEO:GSM274735, GEO:GSM274736, GEO:GSM434324, GEO:GSM784250, GEO:GSM794261, GEO:GSM817063, GEO:GSM843486, GEO:GSM886914, GEO:GSM887980, GEO:GSM1374430, GEO:GSM1374431, GEO:GSM1374432, IARC\_TP53:8200, IARC\_TP53:21263, ICLC:HTL95002, IGRhCellID:Calu1, IZSLER:BS TCL 76, LiGeA:CCLE\_612, LINCS\_HMS:50009, LINCS\_LDP:LCL-1580, PharmacDB:Calu1\_178\_2019, PRIDE:PXD002556, Progenetix:CVCL\_0608, PubChem\_Cell\_line:CVCL\_0608, Wikidata:Q54808423

**ID:** CVCL\_0608

**Record Creation Time:** 20220427T215439+0000

**Record Last Update:** 20260905T174514+0000

---

## Ratings and Alerts

No rating or validation information has been found for Calu-1.

No alerts have been found for Calu-1.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 212 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Brunner JS, et al. (2026) Aspartate availability drives differential engagement of the malate-aspartate shuttle. Molecular cell, 86(5), 954.

Wang J, et al. (2026) Cyclic di-GMP suppresses cancer metastasis by targeting proteasome 26S subunit non-ATPase 3 independently of STING. Signal transduction and targeted therapy, 11(1), 44.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Zhu G, et al. (2026) Accumulated sotorasib-bound KRASG12C reactivates the MAPK pathway and drives sotorasib resistance via the DHX9-RAC1-PAK1 axis. *Cell reports*, 45(5), 117338.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. *Oncogene*, 45(31), 3244.

Baars B, et al. (2026) RAS Mutation-Specific Responses to Paralog- and State-Selective RAS Inhibitors. *Molecular cancer research : MCR*, 24(1), 60.

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. *Biochemical pharmacology*, 243(Pt 2), 117562.

Huart C, et al. (2026) PARP inhibitors induce a senescence phenotype in non-small cell lung carcinoma cell lines. *FEBS open bio*, 16(7), 1370.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD<sup>+</sup> to eradicate KRAS-driven AML. *Cell metabolism*, 38(6), 1113.

Ren D, et al. (2026) Gasdermin C reprograms metabolism through the CAMKK2-AMPK axis to promote lung adenocarcinoma progression and radioresistance. *Cell reports*, 45(6), 117427.

Güngör Ö, et al. (2026) Triphenylphosphonium-triazole hybrids as mitochondria-targeted anticancer agents: design, DNA binding, cytotoxicity study, fluorescent apoptosis imaging and molecular docking. *RSC advances*.

Park VS, et al. (2025) Lipid Composition Alters Ferroptosis Sensitivity. *Cancer research*, 85(22), 4380.

Bratt AS, et al. (2025) Pharmacologic interrogation of USP28 cellular function in p53 signaling. *Cell chemical biology*.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. *Cancer cell*.

Metur SP, et al. (2025) Yeast TIA1 coordinates with Npl3 to promote ATG1 translation during starvation. *Cell reports*, 44(2), 115316.

Guler Kara H, et al. (2025) The G protein-coupled receptor GPR89A is a novel potential therapeutic target to overcome cisplatin resistance in NSCLC Calu1 cells. *The FEBS journal*, 292(14), 3755.

Song X, et al. (2025) Cytosolic cytochrome c represses ferroptosis. *Cell metabolism*, 37(6), 1326.

Negrao MV, et al. (2025) Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*,

31(6), 1069.

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. *Cancer research*, 85(18), 3518.

Pan K, et al. (2025) ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. *The Journal of biological chemistry*, 302(2), 111110.